Traws Pharma, Inc.
About Traws Pharma, Inc.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.8M
- Net income
- $9.2M
- Total assets
- $10.6M
- Market cap
- $20.8M
- Operating margin
- -640.7%
- Net margin
- 328.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.8M
- Operating expenses
- $20.7M
- Operating income
- -$17.9M
- Net income
- $9.2M
- EPS (basic)
- $0.83
- EPS (diluted)
- $0.82
Balance sheet
- Total assets
- $10.6M
- Current assets
- $8.0M
- Total liabilities
- $11.2M
- Current liabilities
- $11.1M
- Shareholders’ equity
- -$629.0K
Cash flow
- Operating cash flow
- -$18.2M
- Investing cash flow
- -$2.6M
- Financing cash flow
- $3.2M
- Net cash flow
- -$17.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $20.8M
- P/E ratio
- 1.7
- EPS (diluted)
- $0.82
- Shares outstanding
- 15.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 25, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $9.2M in FY2025.
- Revenue grew 1135% from FY2024 to FY2025.
- Trading 56% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 1.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Traws Pharma, Inc..
Write a review
News about Traws Pharma, Inc.
News & sentiment via Polygon.io
